StockData
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. (FLNA) stock

FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)

Close on Nov 20, 2026Market cap $30.98MP/E –Yield –

Filana Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Filana Therapeutics's price to sales ratio was 6.3× on Apr 30, 2014, against 17.1× a year earlier. Over the last 2 years it ranged from 6.1× to 26.2×, with a median of 14.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2014Apr 30, 20146.3×−19.9
2013Dec 31, 201326.2×+10.4
2012Apr 30, 201215.8×+3.5
2011Jul 29, 201112.3×–

More Filana Therapeutics figures

See a number that looks wrong?